RU2464992C1 - Method of treating lung cancer - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly oncology, and may be applied in treating lung cancer. In an operation room, immediately before the introduction to general anaesthesia, blood is taken from a patient suffering lung cancer in the amount of 200-300 ml is a sterile container with a haemo-preserving agent and separated; cell mass is selected and combined with carboplatin 150 mg/m² and etoposide 100 mg/m² in a first bottle. Formed plasma is combined with rhoncoleukin 1 mil. IU, incubated at 37°C for 30 minutes in a second bottle. It is followed by the intravenous drop-by-drop introduction of the content of the first bottle, and then of the second bottle. The lung operation for the removal of a malignant growth is completed conventionally.

EFFECT: method allows avoiding side toxic responses on the introduction of the cytostatics, performing the one-stage operating removal of the malignant growth with the introduction of the anti-cancer preparations and improving body resistance, preventing postoperative complications.

4 tbl, 1 ex

Description

The invention relates to medicine, more specifically to oncology, and can be used in the treatment of lung cancer.

There is a method of treating non-small cell lung cancer with the use of polychemotherapy in the preoperative period as one of the components of the combined treatment (Polezhaev A.A. et al. "Experience in the combined treatment of non-small cell lung cancer with the use of neoadjuvant polychemotherapy. - M .: Russian Oncological Journal", 2008. )

As the authors indicate, the proposed method for the treatment of stage II and IIIA lung cancer can increase the 3- and 5-year survival of patients. However, the preoperative chemotherapy recommended by the authors increases the time until the surgical intervention is performed both due to the chemotherapy itself and the relief of its possible complications.

A known method of treating lung cancer is when the antitumor chemotherapy drugs are combined with the patient’s previously taken blood and reinfused to the patient during the main stages of the operation (Patent No. 2242998, Bull. No. 36, dated December 27, 2004, “Method for the treatment of lung cancer”).

The authors propose to administer chemotherapy drugs combined with blood during lung surgery, believing that this prevents hematogenous metastasis and provides an opportunity to avoid transfusion of donor blood.

However, this method does not take into account that surgery is an additional stressor contributing to an increase in the level of immunosuppression, which also increases the likelihood of further distant metastasis.

The aim of the invention is to improve the immune status of patients with lung cancer on the background of intraoperative chemotherapy.

The goal is achieved by the fact that on the day of surgery, before it begins, a patient with lung cancer is sampled in an amount of 200-300 ml in a sterile container with a blood preservative, it is separated, the cell mass is taken and combined with 150 mg / m ² carboplatin and 100 mg / m ² etoposide; the resulting plasma is combined with 1 million ME of roncoleukin, incubated at 37 ° C for 30 minutes, and the contents of the first and then the second vials are intravenously introduced.

An analysis of known methods for the treatment of lung cancer and the claimed allows us to state the presence of novelty and differences.

The novelty of the proposed "Method for the treatment of lung cancer" is the intraoperative administration of roncoleukin, coupled with the patient’s autoplasma and incubated at 37 ° C for 30 minutes.

In accessible open sources of information in Russia, the CIS countries and abroad, a similar method could not be found.

The developed method is industrially applicable. It can be reproduced and repeated many times in health care institutions and specialized clinics of oncological institutions.

The method is as follows.

In the operating room, before being injected into anesthesia in a patient with lung cancer, 200-300 ml of blood are taken in a sterile container with a blood preservative, it is separated, the cell mass is taken and combined with 150 mg / m ^{2 of} carboplatin and 100 mg / m ^{2 of} etoposide. The resulting plasma is combined with 1 million ME of roncoleukin, incubated at 37 ° C for 30 minutes, and the contents of the first and then the second vials are intravenously dripped. The operation on the lung to remove the tumor formation is completed in the usual way.

An example of a specific implementation of the method can serve as extracts from medical records.

1. Patient D., 69 years old, medical history No. C-19653 / I, was hospitalized on December 20, 2010 at the Department of Thoracic Surgery, RNII with a diagnosis of peripheral cancer of the lower lobe of the left lung, pT ₃ N ₀ M ₀ , St PV, 2 C. gr. According to computed tomography, the patient has peripheral cancer of the lower lobe of the left lung 6.0 × 5.5 cm with decay, centralization. Thoracic lymph nodes are not enlarged. There is no fluid in the pleural cavities. The sinuses are free. Upon further examination, data on the presence of distant metastases were not obtained. Before surgery, blood was taken to study the patient's immune status.

date of B-lymphocytes,% CD4% CD8% CD16% CD56% 01/11/2011 eighteen 26 twenty 10 5

On the day of surgery, January 11, 2011, before its start, the patient was sampled autologous blood in the amount of 200 ml in a sterile container with a blood preservative. Blood is divided into two fractions: cell mass and plasma. The cell mass is combined with 150 mg / m ^{2 of} carboplatin and 100 mg / m ^{2 of} etoposide, the plasma is connected with 1 million ME of roncoleukin, the resulting mixtures were incubated at 37 ° C for 30 minutes, the contents of the first and then the second vials were injected intravenously the course of the operation. The operation was performed in the amount of lower left lobectomy with marginal resection of the upper lobe, mediastinal lymphatic dissection. Histological analysis No. 124-127 / 11 - squamous cell carcinoma with a tendency to keratinization, in some places - invasion of the blood vessels of the microvasculature, no metastases in the lymph nodes. The operation and anesthesia proceeded smoothly. There were no complications in the postoperative period. Indicators of immune status:

date of B-lymphocytes,% CD4% CD8% CD16% CD56% 01/25/2011 fourteen 37 25 eighteen 5

Discharged January 26, 2011 in satisfactory condition. It is under surveillance.

2. Patient Ch., 58 years old, medical history No. C-1581 / a, 02/01/2011, was hospitalized in the Department of Thoracic Surgery, RNII with a diagnosis of primary multiple cancer: 1) laryngeal cancer, st. T2N0M0, condition after combined treatment in 2004, 3 cells. column 2) central cancer of the lower lobe of the right lung, pT ₂ N ₀ M ₀ , St IB, 2 C. gr. According to computed tomography, the patient has central cancer of the lower lobe of the right lung 4.6 × 4.0 cm. The lymph nodes of the right root are increased to 2.0 cm. There is no fluid in the pleural cavities. The sinuses are free. Upon further examination, data on the presence of distant metastases were not obtained. Blood taken before surgery to examine the patient’s immune status

date of B-lymphocytes,% CD4% CD8% CD16% CD56% 02/09/2011 eighteen 24 21 12 5

On the day of surgery, 02/09/2011, before its start, the patient was taken autoblood in the amount of 250 ml in a sterile container with a blood preservative. Blood is divided into two fractions: cell mass and plasma. The cell mass is combined with 150 mg / m ² carboplatin and 100 mg / m ² etoposide, the plasma is connected with 1 million ME roncoleukin, the resulting mixtures are incubated at 37 ° C for 30 minutes, the contents of the first and then the second vials are administered intravenously during the operation. The operation was performed in the amount of extended right-sided pneumonectomy. Histological analysis No. 7744-58 / 11 - moderately differentiated squamous cell carcinoma with a tendency to keratinization, infiltrative growth, invasion of blood vessels, lymphatic tissue hyperplasia in the lymph nodes. The operation and anesthesia proceeded smoothly. There were no complications in the postoperative period. Indicators of immune status:

date of B-lymphocytes,% CD4% CD8% CD16% CD56% 02/22/2011 22 33 29th 19 6

Discharged February 22, 2011 in satisfactory condition. It is under surveillance.

Technique-economic efficiency of the "Method for the treatment of lung cancer" lies in the possibility of:

- avoid adverse toxic reactions to the introduction of cytostatics;

- to conduct simultaneous surgical removal of a malignant tumor with the introduction of antitumor drugs;

- improve the immune status and increase the body's resistance;

- avoid postoperative complications.

Claims (1)

A method for the treatment of lung cancer, including intraoperative administration of antitumor chemotherapy drugs connected to the erythrocyte mass of autologous blood, characterized in that immediately after intraoperative infusion of chemotherapy drugs, 1 million ME of roncoleukin incubated with autoplasma is incubated for 30 min at a temperature of 37 ° C; Further, the operation is completed in the usual way.